Amgen is sitting down with regulators for a little frank talk about the safety warnings on Aranesp and Epogen, its two cash cows in the anemia market that were worth $6.6 billion in revenue last year. The biotech giant also says that the Oncologic Drugs Advisory Committee plans to meet and review the ESA drugs in the first quarter of next year. Revenue from the ESA category has been falling steadily as federal and private payers enforce limits on their use. That trend has forced Amgen to restructure and pay more attention to pipeline development projects.
- here's the AFX report on Amgen